niacinamide has been researched along with Carcinoma, Neuroendocrine in 21 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Everolimus was neither additive nor syngergistic in combination with sorafenib or AZD6244." | 5.38 | Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. ( Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C, 2012) |
| " In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors." | 4.89 | [Targeted therapies, prognostic and predictive factors in endocrine oncology]. ( Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M, 2013) |
| "THERE WERE 62 PATIENTS (37 MEN, MEAN AGE: 61 years) treated with sorafenib (62%), sunitinib (22%), and vandetanib (16%) outside of clinical trials; 22 had papillary, five had follicular, five had Hürthle cell, 13 had poorly differentiated, and 17 had medullary thyroid carcinoma (MTC)." | 3.80 | Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. ( Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M, 2014) |
| "Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer (DTC)." | 2.84 | Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. ( Ito, KI; Ito, Y; Kabu, K; Onoda, N; Sugitani, I; Takahashi, S; Tsukada, K; Yamaguchi, I, 2017) |
| "Patients with advanced thyroid cancer derived meaningful clinical benefit from additional therapy with a biologic agent following disease progression on front-line targeted therapy." | 2.78 | Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. ( Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM, 2013) |
| "Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy." | 2.52 | Treatment of advanced thyroid cancer: role of molecularly targeted therapies. ( Covell, LL; Ganti, AK, 2015) |
| "Sorafenib (Nexavar) is a multikinase inhibitor, which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumor cell [c-RAF (proto-oncogene serine/threonine-protein kinase), BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3] and in tumor vessels (c-RAF, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, and platelet-derived growth factor receptor β)." | 2.49 | Sorafenib and thyroid cancer. ( Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S, 2013) |
| "Sorafenib treatment could be considered when vandetanib and cabozantinib are not available or after failing these drugs." | 1.43 | Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis. ( de Castro, G; de Castroneves, LA; de Freitas, RM; Fukushima, JT; Hoff, AO; Hoff, PM; Jorge, AA; Kulcsar, MA; Lima, JV; Negrão, MV; Papadia, C; Simão, EF; Tavares, MR, 2016) |
| "Lenvatinib is an oral potent multi kinase inhibitor [MKI] of different growth factor receptors including VEGFR1/Flt-1, VEGFR2/KDR, VEGFR3, FGFR1,2,3,4, PDGFR-β as well as RET and KIT signaling networks." | 1.43 | Efficacy of lenvatinib in treating thyroid cancer. ( Jarzab, B; Krajewska, J; Kukulska, A, 2016) |
| "Treatment with sorafenib 400 mg twice a day was initiated resulting in a rapid and significant reduction of cortisol and ACTH levels associated with dramatic clinical improvement." | 1.40 | Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome. ( Barroso-Sousa, R; Evangelista, J; Fragoso, MC; Hoff, AO; Kulcsar, MA; Lerario, AM; Lin, CS; Lourenço, DM; Papadia, C, 2014) |
| "Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine." | 1.40 | Thyroid carcinoma, version 2.2014. ( Ball, DW; Byrd, D; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, J; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Sherman, SI; Sturgeon, C; Tuttle, RM; Waguespack, SG; Wang, TN; Wirth, LJ, 2014) |
| "Medullary thyroid cancer (MTC) is frequently associated with mutations in the tyrosine kinase Ret and with increased expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2)." | 1.38 | Anti-tumor activity of motesanib in a medullary thyroid cancer model. ( Bready, J; Canon, J; Coxon, A; Estrada, J; Hughes, P; Kaufman, S; Kendall, R; Osgood, T; Polverino, A; Radinsky, R; Wang, L, 2012) |
| "Everolimus was neither additive nor syngergistic in combination with sorafenib or AZD6244." | 1.38 | Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. ( Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C, 2012) |
| "Medullary thyroid cancer-1." | 1.38 | Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. ( Lin, CI; Lorch, JH; Ruan, DT; Whang, EE, 2012) |
| " 3 patients remain on sorafenib, 2 at a reduced dosage (600 mg/d)." | 1.37 | Rapid response to sorafenib in metastatic medullary thyroid carcinoma. ( Frank-Raue, K; Ganten, M; Kreissl, MC; Raue, F, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, Y | 1 |
| Onoda, N | 1 |
| Ito, KI | 1 |
| Sugitani, I | 1 |
| Takahashi, S | 1 |
| Yamaguchi, I | 1 |
| Kabu, K | 1 |
| Tsukada, K | 1 |
| Martínez-Rodríguez, I | 1 |
| Banzo, I | 1 |
| Carril, JM | 1 |
| Kurzrock, R | 2 |
| Atkins, J | 1 |
| Wheler, J | 2 |
| Fu, S | 1 |
| Naing, A | 2 |
| Busaidy, N | 1 |
| Hong, D | 1 |
| Sherman, S | 1 |
| Fallahi, P | 1 |
| Ferrari, SM | 1 |
| Santini, F | 1 |
| Corrado, A | 1 |
| Materazzi, G | 1 |
| Ulisse, S | 1 |
| Miccoli, P | 1 |
| Antonelli, A | 1 |
| Owonikoko, TK | 1 |
| Chowdry, RP | 1 |
| Chen, Z | 1 |
| Kim, S | 1 |
| Saba, NF | 1 |
| Shin, DM | 1 |
| Khuri, FR | 1 |
| Hescot, S | 1 |
| Baudin, E | 2 |
| Borson-Chazot, F | 1 |
| Lombès, M | 1 |
| Massicotte, MH | 1 |
| Brassard, M | 1 |
| Claude-Desroches, M | 1 |
| Borget, I | 1 |
| Bonichon, F | 1 |
| Giraudet, AL | 1 |
| Do Cao, C | 1 |
| Chougnet, CN | 1 |
| Leboulleux, S | 1 |
| Schlumberger, M | 1 |
| de la Fouchardière, C | 1 |
| Barroso-Sousa, R | 1 |
| Lerario, AM | 1 |
| Evangelista, J | 1 |
| Papadia, C | 2 |
| Lourenço, DM | 1 |
| Lin, CS | 1 |
| Kulcsar, MA | 2 |
| Fragoso, MC | 1 |
| Hoff, AO | 2 |
| Graham, U | 1 |
| Eatock, M | 1 |
| Atkinson, B | 1 |
| Tuttle, RM | 1 |
| Haddad, RI | 1 |
| Ball, DW | 1 |
| Byrd, D | 1 |
| Dickson, P | 1 |
| Duh, QY | 1 |
| Ehya, H | 1 |
| Haymart, M | 1 |
| Hoh, C | 1 |
| Hunt, JP | 1 |
| Iagaru, A | 1 |
| Kandeel, F | 1 |
| Kopp, P | 1 |
| Lamonica, DM | 1 |
| Lydiatt, WM | 1 |
| McCaffrey, J | 1 |
| Moley, JF | 1 |
| Parks, L | 1 |
| Raeburn, CD | 1 |
| Ridge, JA | 1 |
| Ringel, MD | 2 |
| Scheri, RP | 1 |
| Shah, JP | 1 |
| Sherman, SI | 2 |
| Sturgeon, C | 1 |
| Waguespack, SG | 2 |
| Wang, TN | 1 |
| Wirth, LJ | 1 |
| Hoffmann, KG | 1 |
| Hughes, M | 1 |
| Covell, LL | 1 |
| Ganti, AK | 1 |
| Dunna, NR | 1 |
| Kandula, V | 1 |
| Girdhar, A | 1 |
| Pudutha, A | 1 |
| Hussain, T | 1 |
| Bandaru, S | 1 |
| Nayarisseri, A | 1 |
| de Castroneves, LA | 1 |
| Negrão, MV | 1 |
| de Freitas, RM | 1 |
| Lima, JV | 1 |
| Fukushima, JT | 1 |
| Simão, EF | 1 |
| Tavares, MR | 1 |
| Jorge, AA | 1 |
| de Castro, G | 1 |
| Hoff, PM | 1 |
| Krajewska, J | 1 |
| Kukulska, A | 1 |
| Jarzab, B | 1 |
| Spector, E | 1 |
| Franklin, MJ | 1 |
| Truskinovsky, AM | 1 |
| Dudek, AZ | 1 |
| Frank-Raue, K | 1 |
| Ganten, M | 1 |
| Kreissl, MC | 1 |
| Raue, F | 1 |
| Hong, DS | 1 |
| Cabanillas, ME | 1 |
| Tsimberidou, AM | 1 |
| Ye, L | 1 |
| Busaidy, NL | 1 |
| Hernandez, M | 1 |
| El Naggar, AK | 2 |
| Bidyasar, S | 1 |
| Wright, J | 1 |
| Coxon, A | 1 |
| Bready, J | 1 |
| Kaufman, S | 1 |
| Estrada, J | 1 |
| Osgood, T | 1 |
| Canon, J | 1 |
| Wang, L | 1 |
| Radinsky, R | 1 |
| Kendall, R | 1 |
| Hughes, P | 1 |
| Polverino, A | 1 |
| Koh, YW | 1 |
| Shah, MH | 1 |
| Agarwal, K | 1 |
| McCarty, SK | 1 |
| Koo, BS | 1 |
| Brendel, VJ | 1 |
| Wang, C | 1 |
| Porter, K | 1 |
| Jarjoura, D | 1 |
| Saji, M | 1 |
| García-Martín, A | 1 |
| López-Ibarra Lozano, PJ | 1 |
| Triviño-Ibáñez, EM | 1 |
| Escobar-Jiménez, F | 1 |
| Lin, CI | 1 |
| Whang, EE | 1 |
| Lorch, JH | 1 |
| Ruan, DT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies[NCT00215605] | Phase 1 | 85 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers[NCT00244972] | Phase 1 | 74 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma[NCT00121680] | Phase 1 | 115 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor[NCT00495872] | Phase 1 | 204 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for niacinamide and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Sorafenib and thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carci | 2013 |
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free | 2013 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug | 2015 |
4 trials available for niacinamide and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Neuroendocrine; Diarrhea; Drug Resistance, Neopla | 2017 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Surviv | 2013 |
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2011 |
14 other studies available for niacinamide and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Fe | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; | 2014 |
Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome.
Topics: ACTH Syndrome, Ectopic; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Niacinamide; Phenylure | 2014 |
Use of sorafenib in a corticotropin-secreting pancreatic neuroendocrine carcinoma.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Male; Middle | 2014 |
Thyroid carcinoma, version 2.2014.
Topics: Adenocarcinoma; Anilides; Carcinoma, Neuroendocrine; Guidelines as Topic; Humans; Neoplasm Metastasi | 2014 |
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; H | 2015 |
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Sur | 2016 |
Efficacy of lenvatinib in treating thyroid cancer.
Topics: Biomarkers; Calcitonin; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Half-Life; Humans; Niac | 2016 |
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; | 2010 |
Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendo | 2011 |
Anti-tumor activity of motesanib in a medullary thyroid cancer model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cells, Cultured; Female | 2012 |
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidaz | 2012 |
Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
Topics: Carcinoma, Neuroendocrine; Humans; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea | 2013 |
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell | 2012 |